Blastic Plasmacytoid Dendritic Cell Neoplasm Clinical Trial
Official title:
Blastic Plasmacytoid Dendritic Cell Neoplasm in Korean Population: A Multicenter Study
Retrospective study , To analyze the clinical features and treatment outcomes in Korean blastic plasmacytoid dendritic cell neoplasm.
Blastic plasmacytoid dendritic cell neoplasm (BPDCN), with a synonym of blastic NK-cell
lymphoma, agranular CD4+ natural killer cell leukaemia, blastic natural killer
leukaemia/lymphoma, and agranular CD4+CD56+ haematodermic neoplasm/tumour, has been
classified under "acute myeloid leukemia (AML) and related precursor neoplasms" since 2008
according to the World Health Organization (WHO) classification and among "myeloid neoplasm
and acute leukemia" following 2016 revision of WHO classification. The plasmacytoid dendritic
cells originates professional type I interferon-producing cells or plasmacytoid monocytes.
Therefore, the prerequisite for diagnosis of BPDCN is the CD4+ and CD 56+ co-expression
without common lymphoid or myeloid lineage markers1,2. This rare type of malignancy affecting
predominantly elderly man, is reported to comprise 0.44% of hematologic malignancy3 and 0.7%
of cutaneous lymphomas4, and the leukemic presentation or transformation is observed at
initial presentation or even in the course of disease progression5.
Skin in¬volvement is a predominant clinical feature of BPDCN ranging in appearance from small
bruise-like areas to patches, nodules, and ulcerated masses, but lymphadenopathy,
splenomegaly, hepatomegaly are also commonly observed. There is no definite treatment
guideline for BPDCN. Retrospective studies including acute myeloid leukemia (AML) or acute
lymphoblastic leukemia (ALL)/lymphoma-like chemotherapy for management of BPDCN reported
53-89% of high complete remission rates but an eventual very poor overall survival of 12-23
months, with a preponderance of ALL/lymphoma- over AML-like treatment5. Recently, targeted
therapy with SL401, an IL-3 fusion protein which binds to CD123, is promising and the results
of the clinical trial will be unveiled in the near future6.
Although several retrospective and small case series has been published so far7,8, there is
still no multicenter study on BPDCN classified after 2008 WHO classification in Asian
population. This study aims to retrospectively collect data of BPDCN patients from centers
participating the Consortium for improving survival of lymphoma (CISL) and analyze the
clinical features and treatment outcomes in this rare type of hematologic malignancy.
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT03246906 -
Comparison of Triple GVHD Prophylaxis Regimens for Nonmyeloablative or Reduced Intensity Conditioning Unrelated Mobilized Blood Cell Transplantation
|
Phase 2 | |
| Recruiting |
NCT04216524 -
Venetoclax, SL-401, and Chemotherapy for the Treatment of Blastic Plasmacytoid Dendritic Cell Neoplasm
|
Phase 2 | |
| Completed |
NCT00397579 -
DT388IL3 Fusion Protein in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndromes
|
Phase 1/Phase 2 | |
| Terminated |
NCT03075553 -
Nivolumab in Treating Patients With Relapsed or Refractory Peripheral T-cell Lymphoma
|
Phase 2 | |
| Completed |
NCT04317781 -
Tagraxofusp in Treating Patients With Blastic Plasmacytoid Dendritic Cell Neoplasm After Stem Cell Transplant
|
Phase 2 | |
| Recruiting |
NCT03113643 -
SL-401 in Combination With Azacitidine or Azacitidine/Venetoclax in Acute Myeloid Leukemia (AML), High-Risk Myelodysplastic Syndrome (MDS) or Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)
|
Phase 1 | |
| Recruiting |
NCT06013423 -
Cord Blood Transplant, Cyclophosphamide, Fludarabine, and Total-Body Irradiation in Treating Patients With High-Risk Hematologic Diseases
|
Phase 2 | |
| Recruiting |
NCT05362773 -
A Study of MGD024 in Patients With Relapsed or Refractory Hematologic Malignancies
|
Phase 1 | |
| Completed |
NCT02859623 -
Descriptive Study of the Efficacy of Treatments for Blastic Dendritic Cell Neoplasm (BPDCN)
|
N/A | |
| Completed |
NCT01231919 -
MK2206 in Treating Younger Patients With Recurrent or Refractory Solid Tumors or Leukemia
|
Phase 1 | |
| Active, not recruiting |
NCT03386513 -
Study of IMGN632 in Patients With Untreated BPDCN and Relapsed/Refractory BPDCN
|
Phase 1/Phase 2 | |
| Completed |
NCT02652715 -
Salvia Hispanica Seed in Reducing Risk of Disease Recurrence in Patients With Non-Hodgkin Lymphoma
|
N/A | |
| Active, not recruiting |
NCT03404193 -
Venetoclax and Decitabine in Treating Participants With Relapsed/Refractory Acute Myeloid Leukemia or Relapsed High-Risk Myelodysplastic Syndrome
|
Phase 2 | |
| Active, not recruiting |
NCT02220985 -
Selective Depletion of CD45RA+ T Cells From Allogeneic Peripheral Blood Stem Cell Grafts From HLA-Matched Related and Unrelated Donors in Preventing GVHD
|
Phase 2 | |
| Completed |
NCT00014235 -
Fludarabine Phosphate and Total-Body Radiation Followed by Donor Peripheral Blood Stem Cell Transplant and Immunosuppression in Treating Patients With Hematologic Malignancies
|
N/A | |
| Active, not recruiting |
NCT02159495 -
Genetically Modified T-cell Immunotherapy in Treating Patients With Relapsed/Refractory Acute Myeloid Leukemia and Persistent/Recurrent Blastic Plasmacytoid Dendritic Cell Neoplasm
|
Phase 1 | |
| Recruiting |
NCT03779854 -
Naive T Cell Depletion for Preventing Chronic Graft-versus-Host Disease in Children and Young Adults With Blood Cancers Undergoing Donor Stem Cell Transplant
|
Phase 2 | |
| Active, not recruiting |
NCT03485547 -
Study of Venetoclax, a BCL2 Antagonist, for Patients With Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)
|
Phase 1 | |
| Completed |
NCT02730312 -
PH 1 Study to Evaluate Safety and Tolerability of XmAb14045 in Patients With CD123-expressing Hematologic Malignancies
|
Phase 1 |